A Phase III Confirmatory Study of K-237

PHASE3CompletedINTERVENTIONAL
Enrollment

1,030

Participants

Timeline

Start Date

October 22, 2021

Primary Completion Date

August 26, 2022

Study Completion Date

August 26, 2022

Conditions
Covid19
Interventions
DRUG

K-237 0.3-0.4mg/kg (once daily)

Ivermectin 3mg tablet

DRUG

Placebo 0.3-0.4mg/kg (once daily)

Placebo 3mg tablet

Trial Locations (55)

11000

Bamrasnaradura Infectious Diseases Institute, Nonthaburi

40002

Srinagarind Hospital, Khon Kaen

70000

Ratchaburi Hospital, Ratchaburi Provinc

453-0812

Hosokawa Surgical Clinic, Aichi

462-8508

Nagoya City University West Medical Center, Aichi

464-8547

Nagoya City University East Medical Center, Aichi

466-0013

Naika Tonyobyonaika Maejima Iin, Aichi

467-8602

Nagoya City University Hospital, Aichi

509-6134

Tohno Chuo Clinic, Aichi

273-0121

Kamagaya General Hospital, Chiba

273-8556

Japan Community Health care Organization Funabashi Central Hospital, Chiba

286-8520

International University of Health and Welfare Narita Hospital, Chiba

811-3195

National Hospital Organization Fukuokahigashi Medical Center, Fukuoka

814-8525

Fukuoka Kinen Hospital, Fukuoka

370-0829

National Hospital Organization Takasaki General Medical Center, Gunma

734-8530

Hiroshima Prefectural Hospital, Hiroshima

062-8618

Japan Community Health care Organization Hokkaido Hospital, Hokkaido

920-8650

National Hospital Organization Kanazawa Medical Center, Ishikawa

762-8550

Sakaide City Hospital, Kagawa

892-0822

Tenyoukai Central Hospital, Kagoshima

210-0806

Kawasaki Rinko General Hospital, Kanagawa

212-0024

Matsuba Clinic, Kanagawa

220-0004

Maekawa Medical Clinic, Kanagawa

224-0041

Tsuzuki Azuma Clinic Primary care and Rheumatology, Kanagawa

232-0066

Mutsukawa Clinic Primary care and Gastroenterology, Kanagawa

252-0375

Kitasato University Hospital, Kanagawa

861-1196

NHO Kumamoto Saishun Medical Center, Kumamoto

861-4173

Sakura Jyuji Hospital, Sakurajyuji Medical Corporation, Kumamoto

381-2217

Minami Nagano Clinic, Nagano

857-0134

Japan Organization of Occupational Health and Safety Nagasaki Rosai Hospital, Nagasaki

630-0213

Ikoma City Hospital, Nara

940-0861

Nagaoka Chuo General Hospital, Niigata

700-8557

Okayama City General Medical Center Okayama City Hospital, Okayama

700-8558

Okayama University Hospital, Okayama

530-8480

Tazuke Kofukai Medical Research Institute, Kitano Hospital, Osaka

552-0003

Japan Community Health care Organization Osaka Minato Central Hospital, Osaka

598-8577

Rinku General Medical Center, Osaka

525-8585

Omi Medical Center, Shiga

321-0114

Kuramochi Clinic Interpark, Tochigi

103-0028

Tokyo center clinic, Tokyo

108-0073

Tokyo Saiseikai Central Hospital, Tokyo

108-8642

Kitasato University Kitasato Institute Hospital, Tokyo

130-0012

Sumida General Clinic, Tokyo

133-0052

Edogawa Hospital, Tokyo

136-0072

Koto Hospital, Tokyo

153-0051

Mishuku Hospital, Tokyo

177-0051

Shimamura Memorial Hospital, Tokyo

192-0918

Minamino Cardiovascular Hospital, Tokyo

193-0998

Tokyo Medical University Hachioji Medical Center, Tokyo

198-0042

Ome Municipal General Hospital, Tokyo

930-0194

Toyama University Hospital, Toyama

937-0042

Japan Organization of Occupational Health and Safety Toyama Rosai Hospital, Toyama

939-8511

Toyama City Hospital, Toyama

640-8505

Japan Organization of Occupational Health and Safety Wakayama Rosai Hospital, Wakayama

646-8558

National Hospital Organization Minami Wakayama Medical Center, Wakayama

All Listed Sponsors
lead

Kowa Company, Ltd.

INDUSTRY

NCT05056883 - A Phase III Confirmatory Study of K-237 | Biotech Hunter | Biotech Hunter